BIO Would Consider User Fees for FDA Approval of Patient Info

At an FDA public meeting to gather ideas on better ways to present information to patients about prescription medications, BIO said it “is open to discussions” on industry user fees to fund FDA approval of standardized sponsor-created documents. User fees are “something that we could discuss with our membership,” Andrew Emmett, BIO’s managing director of science and regulatory affairs, said in response to a panel member’s question whether the trade group would consider user fees to fund such a program.
Drug Industry Daily